COLITIS, ULCERATIVE

This study is testing three long-acting antibodies, alone or in combination, in 645 people with ulcerative colitis. The goal is to see if they are safe and can improve bowel inflammation over 48 weeks. Participants are joining from a previous study and may have already seen some …

This study tests whether dupilumab can help people with moderate to severe ulcerative colitis that has a certain type of immune cell activity (eosinophilic phenotype). About 68 adults will receive either dupilumab or a placebo for 52 weeks. The main goal is to see if symptoms and…

This study tests an injected drug called guselkumab for people with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. About 418 adults who haven't responded well to other treatments will receive either the…

This study tests a drug called golimumab in children aged 2-17 with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. The goal is to see if the drug can bring about remission (symptom relief) within 6 week…

This study tests whether combining two biologic drugs, guselkumab and golimumab, works better than either drug alone for people with moderate to severe ulcerative colitis. About 577 participants who haven't responded well to other advanced therapies will receive injections of the…

This study follows 159 children aged 2 to 17 who have already completed a prior ustekinumab study for Crohn's disease, ulcerative colitis, or psoriatic arthritis. The goal is to collect long-term safety data by monitoring side effects, lab results, and injection-site reactions. P…

This study tests a drug called guselkumab in children aged 2-17 with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. The goal is to see if the drug can bring the disease under control and keep it in remission for up to 56 weeks. About 112 chi…

This study looks at the long-term safety and effectiveness of balinatunfib, an oral tablet, in adults with Crohn's disease or ulcerative colitis. Participants have already completed a one-year treatment in a previous study. The trial will last up to 107 weeks and includes both do…

This study tests two different doses of TEV-48574 (duvakitug) given as a shot every 4 weeks to adults with moderate to severe ulcerative colitis or Crohn's disease. Participants who completed a previous 14-week study can join. The goal is to see if the drug can keep the disease u…

This Phase 2 trial tests an oral drug called SAR443122 in 187 adults with moderate to severe ulcerative colitis who haven't responded well to other treatments. Participants receive either the drug or a placebo for up to 52 weeks. The goal is to see if the drug can safely help ach…

This early-stage trial is testing a new drug called GSK4528287 for the first time in humans. The goal is to check for side effects and see how the drug behaves in the body. 48 healthy volunteers will receive a single dose, with the amount increased gradually in different groups. …

This study tests three different doses of an experimental drug called MORF-057 in 280 adults with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. The goal is to see if the drug can safely help patients achieve remission, meaning less bleeding, more no…

This study looks at whether health education from nurses can improve quality of life and reduce anxiety and depression in people who have had digestive surgery and now have an ostomy. About 70 adults with permanent or long-term ostomies will take part in workshops and follow-up s…

This study looks at whether acupuncture can reduce disease activity and pain in children with mild-to-moderate Crohn's disease or ulcerative colitis. About 60 kids on stable medication will receive acupuncture alongside their usual care. Researchers will measure changes in sympto…

This study looks at 672 people with active ulcerative colitis to find the best treatment target. Participants are split into three groups: one aiming for symptom relief only, another for symptom plus endoscopic healing, and a third for symptom, endoscopic, and microscopic healing…